AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02767934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05393349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowering the patient and caregiver for early and safe discharge of patients with geriatric hip fractures
Description: Orthopaedic surgeon, geriatrician, physiotherapists, occupational therapists, and nurses will make videos (each 3-5 minutes long) which are available to the patients and caregivers during both the hospitalization period and after discharge. They will complement the therapists' training sessions and allow revision of the contents by the patients and caregivers anytime. The patients and caregivers will be asked to complete an assessment after they view the videos to reinforce the knowledge they learn in the videos. Caregivers can be patient's relatives, friends or domestic helper who can commit to visiting the patient at least two days per week during the early discharge period.
Study NCT00640458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Study NCT03144765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal Total Mesorectal Excision (taTME)
Description: Study procedures consist in 1-team (sequential) or 2-team (combined) low anterior resection with transanal TME using laparoscopic or robotic abdominal assistance.
Study NCT01497717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab (Humira)
Description: Open label pilot trial.~The study includes 3 phases :~1. Open label treatment period of 24 weeks.~2. Extension follow -up (3 years): Patients who responded well to study drug and their disease relapsed within the first 12 weeks following study drug interruption will be eligible to receive the study drug for 3 years in order to comply with the Israeli Ministry of Health requirements.~3. Safety follow-up: For patients who withdraw from either the open label treatment period or extension period, for another 24 weeks.
Study NCT03342014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: 3DPD and UAD acquisitions (10 min)
Study NCT03342014 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: A blood sampling (20 mL) is collected for biomarker analysis (PAPP-A and PlGF) and biological collection.
Study NCT00643773 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Description: capsules are 0.5g, subjects take 5 capsules with every main meal for 6 months In total this is 15 capsules per day
Study NCT00643773 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat flour
Description: Wheat flour
Study NCT02915796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF + CD133(+) cells
Description: Patients in the G-CSF + CD133(+) cells + PTA group, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize CD 133 cells from bone marrow to peripheral blood. After 72-120 hrs, 100 ml suspension of peripheral arterial blood were collected and send to Good Products Manufacturing (GPM) certified laboratory (Shanghai Chen Chuan Biological Material Co. Ltd.) within 24 hrs of obtaining sample to isolate CD 133(+) endothelial progenitor cells (EPC) using magnetic cell separator. Subjects in this group, after vascular PTA treatment, received transarterial infusion of 50 ml suspension of isolated autologous CD 133(+) cells over 30 min via catheter opened into popliteal artery. The infusion of CD 133 cells was repeated after 24 hours.
Study NCT02915796 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Subjects in this group, after vascular PTA treatment, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize EPCs from bone marrow to peripheral blood. But the C133 (+) cells were not isolated from the peripheral blood to infuse transarterially as in G-CSF + CD133(+) + PTA.
Study NCT02915796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous transluminal angioplasty (PTA)
Description: Subjects in this group only underwent below the knee percutaneous transluminal angioplasty .
Study NCT02915796 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: percutaneous transluminal angioplasty (PTA)
Description: Subjects in this group only underwent below the knee percutaneous transluminal angioplasty .
Study NCT02915796 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous transluminal angioplasty (PTA)
Description: Subjects in this group only underwent below the knee percutaneous transluminal angioplasty .
Study NCT02915796 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Neither G-CSF was injected nor CD133(+) cells. Instead, subjects received placebo infusion (50 ml of 0.9% sodium chloride injection ) over 30 min.
Study NCT02002390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fingolimod
Description: A sphingosine-1-phosphate receptor regulator
Study NCT02002390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: A sphingosine-1-phosphate receptor regulator
Study NCT01806558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Molecular Breast Imaging
Description: Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
Study NCT02333474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV mix vaccine
Description: MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), BCG (Bacille Calmette-Guerin vaccine), measles, Serratia and pneumococcus. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
Study NCT02333474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
Study NCT02017106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovenous Laser ablation and concomitant phlebectomies
Study NCT02017106 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous Laser ablation and concomitant phlebectomies
Study NCT00640458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT06440863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: Patients undergoing total knee arthroplasty
Study NCT06440863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip arthroplasty
Description: Patients undergoing total hip arthroplasty
Study NCT02654015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo MIES
Description: Subjects will receive best medical management plus MIES (minimally invasive endoscopic surgery with use of the Apollo System.
Study NCT02654015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: Subjects will receive best medical management for intracranial hemorrhage
Study NCT01142661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin Mesylate: A dose of 1.4 mg/m\^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.
Study NCT02937506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The intervention is to use propofol as anesthesia during a colonoscopy.
Study NCT02937506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Plus Midazolam
Description: The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
Study NCT00658957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gentamicin-collagen sponge
Description: 5 × 5 cm sponge
Study NCT00658957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo collagen sponge
Description: 5 × 5 cm sponge
Study NCT00464139 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopy
Description: Laparoscopy
Study NCT00496262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Fibrinogen Concentrate
Description: Single intravenous infusion of 70 mg/kg body weight
Study NCT02193607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVT-O
Description: Artificial mesh belt is placed in the middle urethra to provide support to remain no leak
Study NCT02193607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Improved reconstruction pelvic surgery
Description: Repair of severe pelvic organ prolapse with mesh.
Study NCT02193607 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Improved reconstruction pelvic surgery
Description: Repair of severe pelvic organ prolapse with mesh.
Study NCT01922960 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: micro-imaging
Description: micro-imaging
Study NCT03330860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Twelve clips regarding maternal and neonatal health topics
Description: Twelve clips regarding maternal and neonatal health topics, designed with mixed 2D and 3D elements, each one about 45 seconds long (prepared based on the best available evidence and validated by clinical experts).
Study NCT03330860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Clip
Description: Control clip with 2D elements about 45 seconds long, containing information on prenatal control and presented in conventional format (narration, static images and on screen text).
Study NCT03904901 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Individuals will receive individual capsules containing the daily dose of lyophilized probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium lactis and Bifidobacterium bifidum) and will be advised to remain at room temperature, ingest with water and drink before bed.
Study NCT03904901 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product had only the excipient, microcrystalline cellulose, and was identical to the active product in relation to color, shape, size and packaging.
Study NCT02305173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Dexamethasone
Description: One dose of intravenous dexamethasone (8 mg) 60 minutes before surgery.
Study NCT02305173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous salin water
Description: Patients of the control group received homologated placebo 60 minutes before surgery.
Study NCT00791986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ULB , LB
Description: ULB: The patients breath in slowly without resistance via the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks.~LB : The patients breath in slowly against resistance of 20 cmH2O provided by the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks.
Study NCT02518607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGB-BP-3
Description: Treatment of CDI
Study NCT03202888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: QuesGen-created mobile responsive website tool, Family Input for Quality and Safety.
Study NCT02758171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Study NCT02758171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Study NCT02758171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Study NCT02758171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Study NCT02518607 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03126422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Pretreatment of different doses of dexmedetomidine
Study NCT02333474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
Study NCT03320993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal with different macronutrient composition
Description: A mixed meal with identical amount of carbohydrates but different content of protein, fat and alcohol will be given
Study NCT03320993 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mixed meal with different macronutrient composition
Description: A mixed meal with identical amount of carbohydrates but different content of protein, fat and alcohol will be given
Study NCT03282994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Cooling System
Description: Cryotherapy
Study NCT02168699 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound examination of the axilla
Study NCT01919671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongxinluo capsule
Description: for 90 days
Study NCT01919671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: for 90 days
Study NCT00879099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Paroxetine 20 mg once a day during two treatment periods. One treatment period lasts for 3 days.
Study NCT00879099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatine capsule once a day during two treatment periods. One treatment period lasts for 3 days.
Study NCT00879099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: timolol maleate
Description: Oftan Timolol 0,5 % eye drop. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
Study NCT00879099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: timolol maleate
Description: Timosan 0,1 % eye gel. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
Study NCT00662454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethinyl estradiol / levonorgestrel
Description: Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
Study NCT04269707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ferric carboxymaltose
Description: IV iron
Study NCT01497275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan
Description: Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4mCi/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi.
Study NCT04069962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CGA coordination by geriatric team including intensive patient coaching and follow-up
Description: In the intervention group, the CGA including geriatric recommendations for interventions will be coordinated by the geriatric team and will be complemented with patient coaching. This intervention aims to support patient empowerment by improving self-efficacy and supporting self-management of existing age-related problems before systemic therapy or occurring during systemic therapy, and includes an individual counselling session at start of systemic therapy to discuss the recommendations with the patient and to determine their priorities.
Study NCT02617888 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CCTA ~ BREAST SHIELDS
Description: Breast shield placement (randomized) among women.
Study NCT02103712 — intervention group
Intervention type: OTHER
Intervention: Qualitative
Study NCT01549600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: psyllium
Description: 1 level tablespoon (\~ 5.1 g psyllium husk in the psyllium product) mixed with at least 8 ounces of water, taken twice daily
Study NCT01549600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Microcrystalline Cellulose
Description: 1 level tablespoon (\~ 1.18 g MCC in the MCC product) mixed with at least 8 ounces of water, taken twice a day
Study NCT02357979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: CO2 - 9.3μm short-pulsed laser irradiation will occur on the occlusal enamel surface. This results in changes in crystal composition and structure, which increase the resistance of dental mineral to dissolution by acid and will work to better prevent dental caries in the occlusal surface of vital teeth when compared to fluoride therapy alone over 12 months.
Study NCT02357979 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride
Description: The Fluoride varnish is painted on the occlusal surface of the tooth. Fluoride varnish makes enamel more acid resistant.
Study NCT01680887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Study NCT01680887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03973788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: A single section of rTMS (2,000 pulses)
Study NCT02569307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
Study NCT02694263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide, Pioglitazone, Gliclazide or Glimepiride) for the treatment of Type 2 Diabetes.
Study NCT02694263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repaglinide
Description: Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide) for the treatment of Type 2 Diabetes.
Study NCT02694263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Pioglitazone) for the treatment of Type 2 Diabetes.
Study NCT02569307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2g once daily dose
Study NCT02569307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo added to TAU
Study NCT02569307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline Plus Omega-3 fatty acids
Description: Minocycline will be administered in 200mg once daily dose and Omega-3 fatty acid 1.2g taken as once daily dose
Study NCT00432627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: one dose of 20 mg/kg/day
Study NCT02631252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Doses ranging from 600-1400mg daily in divided twice daily doses and administered orally.
Study NCT02631252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Dose: 10mg/m2 IVPB in 50ml NS
Study NCT02631252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Dose: 100 mg/m2 administered intravenously in 500 ml of 0.9% sodium chloride
Study NCT04459130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Obesity Program
Description: The program consists of 10 sessions, each lasting 40 minutes. An EOP booklet containing session programs will be distributed to children.~The topics of the sessions are as follows:~Session 1: Healthy lifestyles~* Session 2: Self-esteem and positive thinking, Setting goals Session 3: Stress and Coping, Coping with Emotions in Healthy Ways Session 4: Personality and effective communication~* Session 5: Activity: Time for action Session 6: Nutrition basics Session 7: Reading tags Session 8: Portion size, nutrition and healthy food choices in schools Session 9: Snacks can also be healthy: Healthy choices~* Session 10: Together for a healthy life (Melnyk et al., 2006; 2007; 2009). Detailed information about the sessions is given in annex -3.
Study NCT03788356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training with a device
Study NCT02017106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovenous Laser ablation and sequential phlebectomies